Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
Toshifumi Ozaki, Hiroshi Hatano, Junya Toguchida, Yukihide Iwamoto et al.
Citations
6 citations
Journal
Journal of Clinical Oncology
Topics
Sarcoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
9.11
article
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
Hiroshima University (JP), Kyushu University (JP), Okayama University (JP), Mie University (JP), Oita University (JP), Kyorin University (JP), Tohoku University (JP), Keio University (JP), Kyoto University (JP), Kanagawa Prefectural Hospital Organization (JP), Nagoya University Hospital (JP), Niigata Cancer Center Hospital (JP), Kurume University Hospital (JP), Yokohama City University Hospital (JP), Kyushu Rosai Hospital (JP), Chiba Cancer Center (JP), Sapporo Medical University Hospital (JP), Niigata University Medical and Dental Hospital (JP), Aichi Cancer Center (JP), Kagawa University Hospital (JP), The Cancer Institute Hospital (JP), Japan Clinical Cancer Research Organization (JP), Gifu University (JP), Kanagawa Cancer Center, Kobe University (JP), Yokohama City University (JP)